Global Irinotecan Market

Irinotecan Comprehensive Study by Type (Irinotecan Hydrochloride Injection 40mg, Irinotecan Hydrochloride Injection 100mg, Other), Application (Colon cancer, Rectal cancer), Route of Administration (Oral, Injection) Players and Region - Europe Market Outlook to 2030

Irinotecan Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Irinotecan Market Scope
Irinotecan medication is given by injection into a vein by a health care professional. The dosage relies on your medical condition, body size, and response to treatment. If this medication comes into contact along with your skin, wash the skin immediately and completely with soap and water. If this medication gets into your eyes, mouth, or nose, flush completely with much waters. Indicated as first-line therapy (with 5-fluorouracil and leucovorin) for metastatic colorectal cancer (CRC); it's also indicated for CRC that has recurred or progressed following initial fluorouracil-based therapy. Irinotecan can cause both early and late-onset diarrhea. Both kinds of diarrhea could also be severe and appear to be mediated by different mechanisms. It is usually transient and only infrequently severe. Early-onset diarrhea is assumed to be a part of a cholinergic syndrome mediated by increased anticholinesterase activity of the irinotecan parent compound.



The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Europe Irinotecan market throughout the predicted period.

West-Ward Pharmaceuticals (United States), Pfizer (United States), Teva Pharmaceutical Industries Ltd. (Israel), Actiza Pharmaceutical (India), Taj Pharma (India), Cipla (India), Salius (India), Tecoland Corporation (United States) and ScinoPharm Taiwan, Ltd (Taiwan) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are YAKULT HONSHA CO LTD (Japan) and Jiwan Pharmaceutical Technology (China).

Segmentation Overview
The study have segmented the market of Europe Irinotecan market by Type (Irinotecan Hydrochloride Injection 40mg, Irinotecan Hydrochloride Injection 100mg and Other), by Application (Colon cancer and Rectal cancer) and Region with country level break-up.

On the basis of geography, the market of Irinotecan has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Influencing Trend:
Increased Awareness about Cancer Treatments among People and Increased Government Initiatives for Cancer Awareness

Market Growth Drivers:
Increased Prevalence of Colorectal Cancer among People Worldwide and Rise in the Number of Diagnostic Centres and Hospitals

Restraints:
Side Effects of the Colorectal Cancer Drugs and Stringent Government Rules and Regulations

Opportunities:
Growth in the Healthcare Industry Worldwide and Increasing Number of Online Pharmacies

Market Leaders and their Expansionary Development Strategies
In September 2021, Torrent Pharma and Dr. Reddy's Laboratories are vying to acquire Cipla Ltd, executing this deal could result in medium-term earnings per share (EPS) dilution for both pharmaceutical giants, a report by Kotak Institutional Equities
In September 2018, Avet Pharmaceuticals Inc. announced the immediate availability of Irinotecan Injection, the generic form of the chemotherapy drug Camptosar®, in two latex free, preservative free single dose vials. The new product launch represents Avet’s first entry into the injectable generic market segment and serves as a lead product for its growing oncology product franchise.


Key Target Audience
Pharmaceutical Company, Distributors, Research Professionals and End-Users

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Report Objectives / Segmentation Covered

By Type
  • Irinotecan Hydrochloride Injection 40mg
  • Irinotecan Hydrochloride Injection 100mg
  • Other
By Application
  • Colon cancer
  • Rectal cancer
By Route of Administration
  • Oral
  • Injection

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence of Colorectal Cancer among People Worldwide
      • 3.2.2. Rise in the Number of Diagnostic Centres and Hospitals
    • 3.3. Market Trends
      • 3.3.1. Increased Awareness about Cancer Treatments among People
      • 3.3.2. Increased Government Initiatives for Cancer Awareness
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Europe Irinotecan, by Type, Application, Route of Administration and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Europe Irinotecan (Value)
      • 5.2.1. Europe Irinotecan by: Type (Value)
        • 5.2.1.1. Irinotecan Hydrochloride Injection 40mg
        • 5.2.1.2. Irinotecan Hydrochloride Injection 100mg
        • 5.2.1.3. Other
      • 5.2.2. Europe Irinotecan by: Application (Value)
        • 5.2.2.1. Colon cancer
        • 5.2.2.2. Rectal cancer
      • 5.2.3. Europe Irinotecan by: Route of Administration (Value)
        • 5.2.3.1. Oral
        • 5.2.3.2. Injection
      • 5.2.4. Europe Irinotecan Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Europe Irinotecan (Volume)
      • 5.3.1. Europe Irinotecan by: Type (Volume)
        • 5.3.1.1. Irinotecan Hydrochloride Injection 40mg
        • 5.3.1.2. Irinotecan Hydrochloride Injection 100mg
        • 5.3.1.3. Other
      • 5.3.2. Europe Irinotecan by: Application (Volume)
        • 5.3.2.1. Colon cancer
        • 5.3.2.2. Rectal cancer
      • 5.3.3. Europe Irinotecan by: Route of Administration (Volume)
        • 5.3.3.1. Oral
        • 5.3.3.2. Injection
      • 5.3.4. Europe Irinotecan Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Europe Irinotecan (Price)
      • 5.4.1. Europe Irinotecan by: Type (Price)
  • 6. Irinotecan: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. West-Ward Pharmaceuticals (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Actiza Pharmaceutical (India)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Taj Pharma (India)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Cipla (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Salius (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Tecoland Corporation (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. ScinoPharm Taiwan, Ltd (Taiwan)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Europe Irinotecan Sale, by Type, Application, Route of Administration and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Europe Irinotecan (Value)
      • 7.2.1. Europe Irinotecan by: Type (Value)
        • 7.2.1.1. Irinotecan Hydrochloride Injection 40mg
        • 7.2.1.2. Irinotecan Hydrochloride Injection 100mg
        • 7.2.1.3. Other
      • 7.2.2. Europe Irinotecan by: Application (Value)
        • 7.2.2.1. Colon cancer
        • 7.2.2.2. Rectal cancer
      • 7.2.3. Europe Irinotecan by: Route of Administration (Value)
        • 7.2.3.1. Oral
        • 7.2.3.2. Injection
      • 7.2.4. Europe Irinotecan Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Europe Irinotecan (Volume)
      • 7.3.1. Europe Irinotecan by: Type (Volume)
        • 7.3.1.1. Irinotecan Hydrochloride Injection 40mg
        • 7.3.1.2. Irinotecan Hydrochloride Injection 100mg
        • 7.3.1.3. Other
      • 7.3.2. Europe Irinotecan by: Application (Volume)
        • 7.3.2.1. Colon cancer
        • 7.3.2.2. Rectal cancer
      • 7.3.3. Europe Irinotecan by: Route of Administration (Volume)
        • 7.3.3.1. Oral
        • 7.3.3.2. Injection
      • 7.3.4. Europe Irinotecan Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Europe Irinotecan (Price)
      • 7.4.1. Europe Irinotecan by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Irinotecan: by Type(USD Million)
  • Table 2. Irinotecan Irinotecan Hydrochloride Injection 40mg , by Region USD Million (2018-2023)
  • Table 3. Irinotecan Irinotecan Hydrochloride Injection 100mg , by Region USD Million (2018-2023)
  • Table 4. Irinotecan Other , by Region USD Million (2018-2023)
  • Table 5. Irinotecan: by Application(USD Million)
  • Table 6. Irinotecan Colon cancer , by Region USD Million (2018-2023)
  • Table 7. Irinotecan Rectal cancer , by Region USD Million (2018-2023)
  • Table 8. Irinotecan: by Route of Administration(USD Million)
  • Table 9. Irinotecan Oral , by Region USD Million (2018-2023)
  • Table 10. Irinotecan Injection , by Region USD Million (2018-2023)
  • Table 11. South America Irinotecan, by Country USD Million (2018-2023)
  • Table 12. South America Irinotecan, by Type USD Million (2018-2023)
  • Table 13. South America Irinotecan, by Application USD Million (2018-2023)
  • Table 14. South America Irinotecan, by Route of Administration USD Million (2018-2023)
  • Table 15. Brazil Irinotecan, by Type USD Million (2018-2023)
  • Table 16. Brazil Irinotecan, by Application USD Million (2018-2023)
  • Table 17. Brazil Irinotecan, by Route of Administration USD Million (2018-2023)
  • Table 18. Argentina Irinotecan, by Type USD Million (2018-2023)
  • Table 19. Argentina Irinotecan, by Application USD Million (2018-2023)
  • Table 20. Argentina Irinotecan, by Route of Administration USD Million (2018-2023)
  • Table 21. Rest of South America Irinotecan, by Type USD Million (2018-2023)
  • Table 22. Rest of South America Irinotecan, by Application USD Million (2018-2023)
  • Table 23. Rest of South America Irinotecan, by Route of Administration USD Million (2018-2023)
  • Table 24. Asia Pacific Irinotecan, by Country USD Million (2018-2023)
  • Table 25. Asia Pacific Irinotecan, by Type USD Million (2018-2023)
  • Table 26. Asia Pacific Irinotecan, by Application USD Million (2018-2023)
  • Table 27. Asia Pacific Irinotecan, by Route of Administration USD Million (2018-2023)
  • Table 28. China Irinotecan, by Type USD Million (2018-2023)
  • Table 29. China Irinotecan, by Application USD Million (2018-2023)
  • Table 30. China Irinotecan, by Route of Administration USD Million (2018-2023)
  • Table 31. Japan Irinotecan, by Type USD Million (2018-2023)
  • Table 32. Japan Irinotecan, by Application USD Million (2018-2023)
  • Table 33. Japan Irinotecan, by Route of Administration USD Million (2018-2023)
  • Table 34. India Irinotecan, by Type USD Million (2018-2023)
  • Table 35. India Irinotecan, by Application USD Million (2018-2023)
  • Table 36. India Irinotecan, by Route of Administration USD Million (2018-2023)
  • Table 37. South Korea Irinotecan, by Type USD Million (2018-2023)
  • Table 38. South Korea Irinotecan, by Application USD Million (2018-2023)
  • Table 39. South Korea Irinotecan, by Route of Administration USD Million (2018-2023)
  • Table 40. Taiwan Irinotecan, by Type USD Million (2018-2023)
  • Table 41. Taiwan Irinotecan, by Application USD Million (2018-2023)
  • Table 42. Taiwan Irinotecan, by Route of Administration USD Million (2018-2023)
  • Table 43. Australia Irinotecan, by Type USD Million (2018-2023)
  • Table 44. Australia Irinotecan, by Application USD Million (2018-2023)
  • Table 45. Australia Irinotecan, by Route of Administration USD Million (2018-2023)
  • Table 46. Rest of Asia-Pacific Irinotecan, by Type USD Million (2018-2023)
  • Table 47. Rest of Asia-Pacific Irinotecan, by Application USD Million (2018-2023)
  • Table 48. Rest of Asia-Pacific Irinotecan, by Route of Administration USD Million (2018-2023)
  • Table 49. Europe Irinotecan, by Country USD Million (2018-2023)
  • Table 50. Europe Irinotecan, by Type USD Million (2018-2023)
  • Table 51. Europe Irinotecan, by Application USD Million (2018-2023)
  • Table 52. Europe Irinotecan, by Route of Administration USD Million (2018-2023)
  • Table 53. Germany Irinotecan, by Type USD Million (2018-2023)
  • Table 54. Germany Irinotecan, by Application USD Million (2018-2023)
  • Table 55. Germany Irinotecan, by Route of Administration USD Million (2018-2023)
  • Table 56. France Irinotecan, by Type USD Million (2018-2023)
  • Table 57. France Irinotecan, by Application USD Million (2018-2023)
  • Table 58. France Irinotecan, by Route of Administration USD Million (2018-2023)
  • Table 59. Italy Irinotecan, by Type USD Million (2018-2023)
  • Table 60. Italy Irinotecan, by Application USD Million (2018-2023)
  • Table 61. Italy Irinotecan, by Route of Administration USD Million (2018-2023)
  • Table 62. United Kingdom Irinotecan, by Type USD Million (2018-2023)
  • Table 63. United Kingdom Irinotecan, by Application USD Million (2018-2023)
  • Table 64. United Kingdom Irinotecan, by Route of Administration USD Million (2018-2023)
  • Table 65. Netherlands Irinotecan, by Type USD Million (2018-2023)
  • Table 66. Netherlands Irinotecan, by Application USD Million (2018-2023)
  • Table 67. Netherlands Irinotecan, by Route of Administration USD Million (2018-2023)
  • Table 68. Rest of Europe Irinotecan, by Type USD Million (2018-2023)
  • Table 69. Rest of Europe Irinotecan, by Application USD Million (2018-2023)
  • Table 70. Rest of Europe Irinotecan, by Route of Administration USD Million (2018-2023)
  • Table 71. MEA Irinotecan, by Country USD Million (2018-2023)
  • Table 72. MEA Irinotecan, by Type USD Million (2018-2023)
  • Table 73. MEA Irinotecan, by Application USD Million (2018-2023)
  • Table 74. MEA Irinotecan, by Route of Administration USD Million (2018-2023)
  • Table 75. Middle East Irinotecan, by Type USD Million (2018-2023)
  • Table 76. Middle East Irinotecan, by Application USD Million (2018-2023)
  • Table 77. Middle East Irinotecan, by Route of Administration USD Million (2018-2023)
  • Table 78. Africa Irinotecan, by Type USD Million (2018-2023)
  • Table 79. Africa Irinotecan, by Application USD Million (2018-2023)
  • Table 80. Africa Irinotecan, by Route of Administration USD Million (2018-2023)
  • Table 81. North America Irinotecan, by Country USD Million (2018-2023)
  • Table 82. North America Irinotecan, by Type USD Million (2018-2023)
  • Table 83. North America Irinotecan, by Application USD Million (2018-2023)
  • Table 84. North America Irinotecan, by Route of Administration USD Million (2018-2023)
  • Table 85. United States Irinotecan, by Type USD Million (2018-2023)
  • Table 86. United States Irinotecan, by Application USD Million (2018-2023)
  • Table 87. United States Irinotecan, by Route of Administration USD Million (2018-2023)
  • Table 88. Canada Irinotecan, by Type USD Million (2018-2023)
  • Table 89. Canada Irinotecan, by Application USD Million (2018-2023)
  • Table 90. Canada Irinotecan, by Route of Administration USD Million (2018-2023)
  • Table 91. Mexico Irinotecan, by Type USD Million (2018-2023)
  • Table 92. Mexico Irinotecan, by Application USD Million (2018-2023)
  • Table 93. Mexico Irinotecan, by Route of Administration USD Million (2018-2023)
  • Table 94. Irinotecan Sales: by Type(K Units)
  • Table 95. Irinotecan Sales Irinotecan Hydrochloride Injection 40mg , by Region K Units (2018-2023)
  • Table 96. Irinotecan Sales Irinotecan Hydrochloride Injection 100mg , by Region K Units (2018-2023)
  • Table 97. Irinotecan Sales Other , by Region K Units (2018-2023)
  • Table 98. Irinotecan Sales: by Application(K Units)
  • Table 99. Irinotecan Sales Colon cancer , by Region K Units (2018-2023)
  • Table 100. Irinotecan Sales Rectal cancer , by Region K Units (2018-2023)
  • Table 101. Irinotecan Sales: by Route of Administration(K Units)
  • Table 102. Irinotecan Sales Oral , by Region K Units (2018-2023)
  • Table 103. Irinotecan Sales Injection , by Region K Units (2018-2023)
  • Table 104. South America Irinotecan Sales, by Country K Units (2018-2023)
  • Table 105. South America Irinotecan Sales, by Type K Units (2018-2023)
  • Table 106. South America Irinotecan Sales, by Application K Units (2018-2023)
  • Table 107. South America Irinotecan Sales, by Route of Administration K Units (2018-2023)
  • Table 108. Brazil Irinotecan Sales, by Type K Units (2018-2023)
  • Table 109. Brazil Irinotecan Sales, by Application K Units (2018-2023)
  • Table 110. Brazil Irinotecan Sales, by Route of Administration K Units (2018-2023)
  • Table 111. Argentina Irinotecan Sales, by Type K Units (2018-2023)
  • Table 112. Argentina Irinotecan Sales, by Application K Units (2018-2023)
  • Table 113. Argentina Irinotecan Sales, by Route of Administration K Units (2018-2023)
  • Table 114. Rest of South America Irinotecan Sales, by Type K Units (2018-2023)
  • Table 115. Rest of South America Irinotecan Sales, by Application K Units (2018-2023)
  • Table 116. Rest of South America Irinotecan Sales, by Route of Administration K Units (2018-2023)
  • Table 117. Asia Pacific Irinotecan Sales, by Country K Units (2018-2023)
  • Table 118. Asia Pacific Irinotecan Sales, by Type K Units (2018-2023)
  • Table 119. Asia Pacific Irinotecan Sales, by Application K Units (2018-2023)
  • Table 120. Asia Pacific Irinotecan Sales, by Route of Administration K Units (2018-2023)
  • Table 121. China Irinotecan Sales, by Type K Units (2018-2023)
  • Table 122. China Irinotecan Sales, by Application K Units (2018-2023)
  • Table 123. China Irinotecan Sales, by Route of Administration K Units (2018-2023)
  • Table 124. Japan Irinotecan Sales, by Type K Units (2018-2023)
  • Table 125. Japan Irinotecan Sales, by Application K Units (2018-2023)
  • Table 126. Japan Irinotecan Sales, by Route of Administration K Units (2018-2023)
  • Table 127. India Irinotecan Sales, by Type K Units (2018-2023)
  • Table 128. India Irinotecan Sales, by Application K Units (2018-2023)
  • Table 129. India Irinotecan Sales, by Route of Administration K Units (2018-2023)
  • Table 130. South Korea Irinotecan Sales, by Type K Units (2018-2023)
  • Table 131. South Korea Irinotecan Sales, by Application K Units (2018-2023)
  • Table 132. South Korea Irinotecan Sales, by Route of Administration K Units (2018-2023)
  • Table 133. Taiwan Irinotecan Sales, by Type K Units (2018-2023)
  • Table 134. Taiwan Irinotecan Sales, by Application K Units (2018-2023)
  • Table 135. Taiwan Irinotecan Sales, by Route of Administration K Units (2018-2023)
  • Table 136. Australia Irinotecan Sales, by Type K Units (2018-2023)
  • Table 137. Australia Irinotecan Sales, by Application K Units (2018-2023)
  • Table 138. Australia Irinotecan Sales, by Route of Administration K Units (2018-2023)
  • Table 139. Rest of Asia-Pacific Irinotecan Sales, by Type K Units (2018-2023)
  • Table 140. Rest of Asia-Pacific Irinotecan Sales, by Application K Units (2018-2023)
  • Table 141. Rest of Asia-Pacific Irinotecan Sales, by Route of Administration K Units (2018-2023)
  • Table 142. Europe Irinotecan Sales, by Country K Units (2018-2023)
  • Table 143. Europe Irinotecan Sales, by Type K Units (2018-2023)
  • Table 144. Europe Irinotecan Sales, by Application K Units (2018-2023)
  • Table 145. Europe Irinotecan Sales, by Route of Administration K Units (2018-2023)
  • Table 146. Germany Irinotecan Sales, by Type K Units (2018-2023)
  • Table 147. Germany Irinotecan Sales, by Application K Units (2018-2023)
  • Table 148. Germany Irinotecan Sales, by Route of Administration K Units (2018-2023)
  • Table 149. France Irinotecan Sales, by Type K Units (2018-2023)
  • Table 150. France Irinotecan Sales, by Application K Units (2018-2023)
  • Table 151. France Irinotecan Sales, by Route of Administration K Units (2018-2023)
  • Table 152. Italy Irinotecan Sales, by Type K Units (2018-2023)
  • Table 153. Italy Irinotecan Sales, by Application K Units (2018-2023)
  • Table 154. Italy Irinotecan Sales, by Route of Administration K Units (2018-2023)
  • Table 155. United Kingdom Irinotecan Sales, by Type K Units (2018-2023)
  • Table 156. United Kingdom Irinotecan Sales, by Application K Units (2018-2023)
  • Table 157. United Kingdom Irinotecan Sales, by Route of Administration K Units (2018-2023)
  • Table 158. Netherlands Irinotecan Sales, by Type K Units (2018-2023)
  • Table 159. Netherlands Irinotecan Sales, by Application K Units (2018-2023)
  • Table 160. Netherlands Irinotecan Sales, by Route of Administration K Units (2018-2023)
  • Table 161. Rest of Europe Irinotecan Sales, by Type K Units (2018-2023)
  • Table 162. Rest of Europe Irinotecan Sales, by Application K Units (2018-2023)
  • Table 163. Rest of Europe Irinotecan Sales, by Route of Administration K Units (2018-2023)
  • Table 164. MEA Irinotecan Sales, by Country K Units (2018-2023)
  • Table 165. MEA Irinotecan Sales, by Type K Units (2018-2023)
  • Table 166. MEA Irinotecan Sales, by Application K Units (2018-2023)
  • Table 167. MEA Irinotecan Sales, by Route of Administration K Units (2018-2023)
  • Table 168. Middle East Irinotecan Sales, by Type K Units (2018-2023)
  • Table 169. Middle East Irinotecan Sales, by Application K Units (2018-2023)
  • Table 170. Middle East Irinotecan Sales, by Route of Administration K Units (2018-2023)
  • Table 171. Africa Irinotecan Sales, by Type K Units (2018-2023)
  • Table 172. Africa Irinotecan Sales, by Application K Units (2018-2023)
  • Table 173. Africa Irinotecan Sales, by Route of Administration K Units (2018-2023)
  • Table 174. North America Irinotecan Sales, by Country K Units (2018-2023)
  • Table 175. North America Irinotecan Sales, by Type K Units (2018-2023)
  • Table 176. North America Irinotecan Sales, by Application K Units (2018-2023)
  • Table 177. North America Irinotecan Sales, by Route of Administration K Units (2018-2023)
  • Table 178. United States Irinotecan Sales, by Type K Units (2018-2023)
  • Table 179. United States Irinotecan Sales, by Application K Units (2018-2023)
  • Table 180. United States Irinotecan Sales, by Route of Administration K Units (2018-2023)
  • Table 181. Canada Irinotecan Sales, by Type K Units (2018-2023)
  • Table 182. Canada Irinotecan Sales, by Application K Units (2018-2023)
  • Table 183. Canada Irinotecan Sales, by Route of Administration K Units (2018-2023)
  • Table 184. Mexico Irinotecan Sales, by Type K Units (2018-2023)
  • Table 185. Mexico Irinotecan Sales, by Application K Units (2018-2023)
  • Table 186. Mexico Irinotecan Sales, by Route of Administration K Units (2018-2023)
  • Table 187. Irinotecan: by Type(USD/Units)
  • Table 188. Company Basic Information, Sales Area and Its Competitors
  • Table 189. Company Basic Information, Sales Area and Its Competitors
  • Table 190. Company Basic Information, Sales Area and Its Competitors
  • Table 191. Company Basic Information, Sales Area and Its Competitors
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Irinotecan: by Type(USD Million)
  • Table 198. Irinotecan Irinotecan Hydrochloride Injection 40mg , by Region USD Million (2025-2030)
  • Table 199. Irinotecan Irinotecan Hydrochloride Injection 100mg , by Region USD Million (2025-2030)
  • Table 200. Irinotecan Other , by Region USD Million (2025-2030)
  • Table 201. Irinotecan: by Application(USD Million)
  • Table 202. Irinotecan Colon cancer , by Region USD Million (2025-2030)
  • Table 203. Irinotecan Rectal cancer , by Region USD Million (2025-2030)
  • Table 204. Irinotecan: by Route of Administration(USD Million)
  • Table 205. Irinotecan Oral , by Region USD Million (2025-2030)
  • Table 206. Irinotecan Injection , by Region USD Million (2025-2030)
  • Table 207. South America Irinotecan, by Country USD Million (2025-2030)
  • Table 208. South America Irinotecan, by Type USD Million (2025-2030)
  • Table 209. South America Irinotecan, by Application USD Million (2025-2030)
  • Table 210. South America Irinotecan, by Route of Administration USD Million (2025-2030)
  • Table 211. Brazil Irinotecan, by Type USD Million (2025-2030)
  • Table 212. Brazil Irinotecan, by Application USD Million (2025-2030)
  • Table 213. Brazil Irinotecan, by Route of Administration USD Million (2025-2030)
  • Table 214. Argentina Irinotecan, by Type USD Million (2025-2030)
  • Table 215. Argentina Irinotecan, by Application USD Million (2025-2030)
  • Table 216. Argentina Irinotecan, by Route of Administration USD Million (2025-2030)
  • Table 217. Rest of South America Irinotecan, by Type USD Million (2025-2030)
  • Table 218. Rest of South America Irinotecan, by Application USD Million (2025-2030)
  • Table 219. Rest of South America Irinotecan, by Route of Administration USD Million (2025-2030)
  • Table 220. Asia Pacific Irinotecan, by Country USD Million (2025-2030)
  • Table 221. Asia Pacific Irinotecan, by Type USD Million (2025-2030)
  • Table 222. Asia Pacific Irinotecan, by Application USD Million (2025-2030)
  • Table 223. Asia Pacific Irinotecan, by Route of Administration USD Million (2025-2030)
  • Table 224. China Irinotecan, by Type USD Million (2025-2030)
  • Table 225. China Irinotecan, by Application USD Million (2025-2030)
  • Table 226. China Irinotecan, by Route of Administration USD Million (2025-2030)
  • Table 227. Japan Irinotecan, by Type USD Million (2025-2030)
  • Table 228. Japan Irinotecan, by Application USD Million (2025-2030)
  • Table 229. Japan Irinotecan, by Route of Administration USD Million (2025-2030)
  • Table 230. India Irinotecan, by Type USD Million (2025-2030)
  • Table 231. India Irinotecan, by Application USD Million (2025-2030)
  • Table 232. India Irinotecan, by Route of Administration USD Million (2025-2030)
  • Table 233. South Korea Irinotecan, by Type USD Million (2025-2030)
  • Table 234. South Korea Irinotecan, by Application USD Million (2025-2030)
  • Table 235. South Korea Irinotecan, by Route of Administration USD Million (2025-2030)
  • Table 236. Taiwan Irinotecan, by Type USD Million (2025-2030)
  • Table 237. Taiwan Irinotecan, by Application USD Million (2025-2030)
  • Table 238. Taiwan Irinotecan, by Route of Administration USD Million (2025-2030)
  • Table 239. Australia Irinotecan, by Type USD Million (2025-2030)
  • Table 240. Australia Irinotecan, by Application USD Million (2025-2030)
  • Table 241. Australia Irinotecan, by Route of Administration USD Million (2025-2030)
  • Table 242. Rest of Asia-Pacific Irinotecan, by Type USD Million (2025-2030)
  • Table 243. Rest of Asia-Pacific Irinotecan, by Application USD Million (2025-2030)
  • Table 244. Rest of Asia-Pacific Irinotecan, by Route of Administration USD Million (2025-2030)
  • Table 245. Europe Irinotecan, by Country USD Million (2025-2030)
  • Table 246. Europe Irinotecan, by Type USD Million (2025-2030)
  • Table 247. Europe Irinotecan, by Application USD Million (2025-2030)
  • Table 248. Europe Irinotecan, by Route of Administration USD Million (2025-2030)
  • Table 249. Germany Irinotecan, by Type USD Million (2025-2030)
  • Table 250. Germany Irinotecan, by Application USD Million (2025-2030)
  • Table 251. Germany Irinotecan, by Route of Administration USD Million (2025-2030)
  • Table 252. France Irinotecan, by Type USD Million (2025-2030)
  • Table 253. France Irinotecan, by Application USD Million (2025-2030)
  • Table 254. France Irinotecan, by Route of Administration USD Million (2025-2030)
  • Table 255. Italy Irinotecan, by Type USD Million (2025-2030)
  • Table 256. Italy Irinotecan, by Application USD Million (2025-2030)
  • Table 257. Italy Irinotecan, by Route of Administration USD Million (2025-2030)
  • Table 258. United Kingdom Irinotecan, by Type USD Million (2025-2030)
  • Table 259. United Kingdom Irinotecan, by Application USD Million (2025-2030)
  • Table 260. United Kingdom Irinotecan, by Route of Administration USD Million (2025-2030)
  • Table 261. Netherlands Irinotecan, by Type USD Million (2025-2030)
  • Table 262. Netherlands Irinotecan, by Application USD Million (2025-2030)
  • Table 263. Netherlands Irinotecan, by Route of Administration USD Million (2025-2030)
  • Table 264. Rest of Europe Irinotecan, by Type USD Million (2025-2030)
  • Table 265. Rest of Europe Irinotecan, by Application USD Million (2025-2030)
  • Table 266. Rest of Europe Irinotecan, by Route of Administration USD Million (2025-2030)
  • Table 267. MEA Irinotecan, by Country USD Million (2025-2030)
  • Table 268. MEA Irinotecan, by Type USD Million (2025-2030)
  • Table 269. MEA Irinotecan, by Application USD Million (2025-2030)
  • Table 270. MEA Irinotecan, by Route of Administration USD Million (2025-2030)
  • Table 271. Middle East Irinotecan, by Type USD Million (2025-2030)
  • Table 272. Middle East Irinotecan, by Application USD Million (2025-2030)
  • Table 273. Middle East Irinotecan, by Route of Administration USD Million (2025-2030)
  • Table 274. Africa Irinotecan, by Type USD Million (2025-2030)
  • Table 275. Africa Irinotecan, by Application USD Million (2025-2030)
  • Table 276. Africa Irinotecan, by Route of Administration USD Million (2025-2030)
  • Table 277. North America Irinotecan, by Country USD Million (2025-2030)
  • Table 278. North America Irinotecan, by Type USD Million (2025-2030)
  • Table 279. North America Irinotecan, by Application USD Million (2025-2030)
  • Table 280. North America Irinotecan, by Route of Administration USD Million (2025-2030)
  • Table 281. United States Irinotecan, by Type USD Million (2025-2030)
  • Table 282. United States Irinotecan, by Application USD Million (2025-2030)
  • Table 283. United States Irinotecan, by Route of Administration USD Million (2025-2030)
  • Table 284. Canada Irinotecan, by Type USD Million (2025-2030)
  • Table 285. Canada Irinotecan, by Application USD Million (2025-2030)
  • Table 286. Canada Irinotecan, by Route of Administration USD Million (2025-2030)
  • Table 287. Mexico Irinotecan, by Type USD Million (2025-2030)
  • Table 288. Mexico Irinotecan, by Application USD Million (2025-2030)
  • Table 289. Mexico Irinotecan, by Route of Administration USD Million (2025-2030)
  • Table 290. Irinotecan Sales: by Type(K Units)
  • Table 291. Irinotecan Sales Irinotecan Hydrochloride Injection 40mg , by Region K Units (2025-2030)
  • Table 292. Irinotecan Sales Irinotecan Hydrochloride Injection 100mg , by Region K Units (2025-2030)
  • Table 293. Irinotecan Sales Other , by Region K Units (2025-2030)
  • Table 294. Irinotecan Sales: by Application(K Units)
  • Table 295. Irinotecan Sales Colon cancer , by Region K Units (2025-2030)
  • Table 296. Irinotecan Sales Rectal cancer , by Region K Units (2025-2030)
  • Table 297. Irinotecan Sales: by Route of Administration(K Units)
  • Table 298. Irinotecan Sales Oral , by Region K Units (2025-2030)
  • Table 299. Irinotecan Sales Injection , by Region K Units (2025-2030)
  • Table 300. South America Irinotecan Sales, by Country K Units (2025-2030)
  • Table 301. South America Irinotecan Sales, by Type K Units (2025-2030)
  • Table 302. South America Irinotecan Sales, by Application K Units (2025-2030)
  • Table 303. South America Irinotecan Sales, by Route of Administration K Units (2025-2030)
  • Table 304. Brazil Irinotecan Sales, by Type K Units (2025-2030)
  • Table 305. Brazil Irinotecan Sales, by Application K Units (2025-2030)
  • Table 306. Brazil Irinotecan Sales, by Route of Administration K Units (2025-2030)
  • Table 307. Argentina Irinotecan Sales, by Type K Units (2025-2030)
  • Table 308. Argentina Irinotecan Sales, by Application K Units (2025-2030)
  • Table 309. Argentina Irinotecan Sales, by Route of Administration K Units (2025-2030)
  • Table 310. Rest of South America Irinotecan Sales, by Type K Units (2025-2030)
  • Table 311. Rest of South America Irinotecan Sales, by Application K Units (2025-2030)
  • Table 312. Rest of South America Irinotecan Sales, by Route of Administration K Units (2025-2030)
  • Table 313. Asia Pacific Irinotecan Sales, by Country K Units (2025-2030)
  • Table 314. Asia Pacific Irinotecan Sales, by Type K Units (2025-2030)
  • Table 315. Asia Pacific Irinotecan Sales, by Application K Units (2025-2030)
  • Table 316. Asia Pacific Irinotecan Sales, by Route of Administration K Units (2025-2030)
  • Table 317. China Irinotecan Sales, by Type K Units (2025-2030)
  • Table 318. China Irinotecan Sales, by Application K Units (2025-2030)
  • Table 319. China Irinotecan Sales, by Route of Administration K Units (2025-2030)
  • Table 320. Japan Irinotecan Sales, by Type K Units (2025-2030)
  • Table 321. Japan Irinotecan Sales, by Application K Units (2025-2030)
  • Table 322. Japan Irinotecan Sales, by Route of Administration K Units (2025-2030)
  • Table 323. India Irinotecan Sales, by Type K Units (2025-2030)
  • Table 324. India Irinotecan Sales, by Application K Units (2025-2030)
  • Table 325. India Irinotecan Sales, by Route of Administration K Units (2025-2030)
  • Table 326. South Korea Irinotecan Sales, by Type K Units (2025-2030)
  • Table 327. South Korea Irinotecan Sales, by Application K Units (2025-2030)
  • Table 328. South Korea Irinotecan Sales, by Route of Administration K Units (2025-2030)
  • Table 329. Taiwan Irinotecan Sales, by Type K Units (2025-2030)
  • Table 330. Taiwan Irinotecan Sales, by Application K Units (2025-2030)
  • Table 331. Taiwan Irinotecan Sales, by Route of Administration K Units (2025-2030)
  • Table 332. Australia Irinotecan Sales, by Type K Units (2025-2030)
  • Table 333. Australia Irinotecan Sales, by Application K Units (2025-2030)
  • Table 334. Australia Irinotecan Sales, by Route of Administration K Units (2025-2030)
  • Table 335. Rest of Asia-Pacific Irinotecan Sales, by Type K Units (2025-2030)
  • Table 336. Rest of Asia-Pacific Irinotecan Sales, by Application K Units (2025-2030)
  • Table 337. Rest of Asia-Pacific Irinotecan Sales, by Route of Administration K Units (2025-2030)
  • Table 338. Europe Irinotecan Sales, by Country K Units (2025-2030)
  • Table 339. Europe Irinotecan Sales, by Type K Units (2025-2030)
  • Table 340. Europe Irinotecan Sales, by Application K Units (2025-2030)
  • Table 341. Europe Irinotecan Sales, by Route of Administration K Units (2025-2030)
  • Table 342. Germany Irinotecan Sales, by Type K Units (2025-2030)
  • Table 343. Germany Irinotecan Sales, by Application K Units (2025-2030)
  • Table 344. Germany Irinotecan Sales, by Route of Administration K Units (2025-2030)
  • Table 345. France Irinotecan Sales, by Type K Units (2025-2030)
  • Table 346. France Irinotecan Sales, by Application K Units (2025-2030)
  • Table 347. France Irinotecan Sales, by Route of Administration K Units (2025-2030)
  • Table 348. Italy Irinotecan Sales, by Type K Units (2025-2030)
  • Table 349. Italy Irinotecan Sales, by Application K Units (2025-2030)
  • Table 350. Italy Irinotecan Sales, by Route of Administration K Units (2025-2030)
  • Table 351. United Kingdom Irinotecan Sales, by Type K Units (2025-2030)
  • Table 352. United Kingdom Irinotecan Sales, by Application K Units (2025-2030)
  • Table 353. United Kingdom Irinotecan Sales, by Route of Administration K Units (2025-2030)
  • Table 354. Netherlands Irinotecan Sales, by Type K Units (2025-2030)
  • Table 355. Netherlands Irinotecan Sales, by Application K Units (2025-2030)
  • Table 356. Netherlands Irinotecan Sales, by Route of Administration K Units (2025-2030)
  • Table 357. Rest of Europe Irinotecan Sales, by Type K Units (2025-2030)
  • Table 358. Rest of Europe Irinotecan Sales, by Application K Units (2025-2030)
  • Table 359. Rest of Europe Irinotecan Sales, by Route of Administration K Units (2025-2030)
  • Table 360. MEA Irinotecan Sales, by Country K Units (2025-2030)
  • Table 361. MEA Irinotecan Sales, by Type K Units (2025-2030)
  • Table 362. MEA Irinotecan Sales, by Application K Units (2025-2030)
  • Table 363. MEA Irinotecan Sales, by Route of Administration K Units (2025-2030)
  • Table 364. Middle East Irinotecan Sales, by Type K Units (2025-2030)
  • Table 365. Middle East Irinotecan Sales, by Application K Units (2025-2030)
  • Table 366. Middle East Irinotecan Sales, by Route of Administration K Units (2025-2030)
  • Table 367. Africa Irinotecan Sales, by Type K Units (2025-2030)
  • Table 368. Africa Irinotecan Sales, by Application K Units (2025-2030)
  • Table 369. Africa Irinotecan Sales, by Route of Administration K Units (2025-2030)
  • Table 370. North America Irinotecan Sales, by Country K Units (2025-2030)
  • Table 371. North America Irinotecan Sales, by Type K Units (2025-2030)
  • Table 372. North America Irinotecan Sales, by Application K Units (2025-2030)
  • Table 373. North America Irinotecan Sales, by Route of Administration K Units (2025-2030)
  • Table 374. United States Irinotecan Sales, by Type K Units (2025-2030)
  • Table 375. United States Irinotecan Sales, by Application K Units (2025-2030)
  • Table 376. United States Irinotecan Sales, by Route of Administration K Units (2025-2030)
  • Table 377. Canada Irinotecan Sales, by Type K Units (2025-2030)
  • Table 378. Canada Irinotecan Sales, by Application K Units (2025-2030)
  • Table 379. Canada Irinotecan Sales, by Route of Administration K Units (2025-2030)
  • Table 380. Mexico Irinotecan Sales, by Type K Units (2025-2030)
  • Table 381. Mexico Irinotecan Sales, by Application K Units (2025-2030)
  • Table 382. Mexico Irinotecan Sales, by Route of Administration K Units (2025-2030)
  • Table 383. Irinotecan: by Type(USD/Units)
  • Table 384. Research Programs/Design for This Report
  • Table 385. Key Data Information from Secondary Sources
  • Table 386. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Europe Irinotecan: by Type USD Million (2018-2023)
  • Figure 5. Europe Irinotecan: by Application USD Million (2018-2023)
  • Figure 6. Europe Irinotecan: by Route of Administration USD Million (2018-2023)
  • Figure 7. South America Irinotecan Share (%), by Country
  • Figure 8. Asia Pacific Irinotecan Share (%), by Country
  • Figure 9. Europe Irinotecan Share (%), by Country
  • Figure 10. MEA Irinotecan Share (%), by Country
  • Figure 11. North America Irinotecan Share (%), by Country
  • Figure 12. Europe Irinotecan: by Type K Units (2018-2023)
  • Figure 13. Europe Irinotecan: by Application K Units (2018-2023)
  • Figure 14. Europe Irinotecan: by Route of Administration K Units (2018-2023)
  • Figure 15. South America Irinotecan Share (%), by Country
  • Figure 16. Asia Pacific Irinotecan Share (%), by Country
  • Figure 17. Europe Irinotecan Share (%), by Country
  • Figure 18. MEA Irinotecan Share (%), by Country
  • Figure 19. North America Irinotecan Share (%), by Country
  • Figure 20. Europe Irinotecan: by Type USD/Units (2018-2023)
  • Figure 21. Europe Irinotecan share by Players 2023 (%)
  • Figure 22. Europe Irinotecan share by Players (Top 3) 2023(%)
  • Figure 23. Europe Irinotecan share by Players (Top 5) 2023(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. West-Ward Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 26. West-Ward Pharmaceuticals (United States) Revenue: by Geography 2023
  • Figure 27. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 28. Pfizer (United States) Revenue: by Geography 2023
  • Figure 29. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 30. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2023
  • Figure 31. Actiza Pharmaceutical (India) Revenue, Net Income and Gross profit
  • Figure 32. Actiza Pharmaceutical (India) Revenue: by Geography 2023
  • Figure 33. Taj Pharma (India) Revenue, Net Income and Gross profit
  • Figure 34. Taj Pharma (India) Revenue: by Geography 2023
  • Figure 35. Cipla (India) Revenue, Net Income and Gross profit
  • Figure 36. Cipla (India) Revenue: by Geography 2023
  • Figure 37. Salius (India) Revenue, Net Income and Gross profit
  • Figure 38. Salius (India) Revenue: by Geography 2023
  • Figure 39. Tecoland Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 40. Tecoland Corporation (United States) Revenue: by Geography 2023
  • Figure 41. ScinoPharm Taiwan, Ltd (Taiwan) Revenue, Net Income and Gross profit
  • Figure 42. ScinoPharm Taiwan, Ltd (Taiwan) Revenue: by Geography 2023
  • Figure 43. Europe Irinotecan: by Type USD Million (2025-2030)
  • Figure 44. Europe Irinotecan: by Application USD Million (2025-2030)
  • Figure 45. Europe Irinotecan: by Route of Administration USD Million (2025-2030)
  • Figure 46. South America Irinotecan Share (%), by Country
  • Figure 47. Asia Pacific Irinotecan Share (%), by Country
  • Figure 48. Europe Irinotecan Share (%), by Country
  • Figure 49. MEA Irinotecan Share (%), by Country
  • Figure 50. North America Irinotecan Share (%), by Country
  • Figure 51. Europe Irinotecan: by Type K Units (2025-2030)
  • Figure 52. Europe Irinotecan: by Application K Units (2025-2030)
  • Figure 53. Europe Irinotecan: by Route of Administration K Units (2025-2030)
  • Figure 54. South America Irinotecan Share (%), by Country
  • Figure 55. Asia Pacific Irinotecan Share (%), by Country
  • Figure 56. Europe Irinotecan Share (%), by Country
  • Figure 57. MEA Irinotecan Share (%), by Country
  • Figure 58. North America Irinotecan Share (%), by Country
  • Figure 59. Europe Irinotecan: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • West-Ward Pharmaceuticals (United States)
  • Pfizer (United States)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Actiza Pharmaceutical (India)
  • Taj Pharma (India)
  • Cipla (India)
  • Salius (India)
  • Tecoland Corporation (United States)
  • ScinoPharm Taiwan, Ltd (Taiwan)
Additional players considered in the study are as follows:
YAKULT HONSHA CO LTD (Japan) , Jiwan Pharmaceutical Technology (China)
Select User Access Type

Key Highlights of Report


Mar 2024 232 Pages 68 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Irinotecan Market Quantitative research analysis
Global Irinotecan Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Irinotecan study can be customized to meet your requirements. The market size breakdown by type, by end-use application.
The Irinotecan Market is gaining popularity and expected to see strong valuation by 2030 .
According to AMA, the Europe Irinotecan market is expected to see growth rate of xx%.
The Irinotecan market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete of companies available in our research coverage.

Know More About Global Irinotecan Market Report?

Have a Query? Click Here

Other Related Reports

Tobramycin Eye Drop Comprehensive Study by Type (Tobramycin and dexamethasone ophthalmic suspension, Tobramycin ophthalmic suspension, Other tobramycin Combination), Application (Adult, Children), En...
$ 3650
Policresulen Comprehensive Study by Type (Gels, Suppositories, Lotion, Implants, Soft Cream, Injection, Tablets, Capsule, Other), Application (Department Of Gynaecology, Surgery And Dermatology, Kouq...
$ 3650
mRNA Cancer Vaccines and Therapeutics Comprehensive Study by Type (Adeno Carcinomas, Mucinous Carcinomas, Adenosquamous Carcinomas), Application (Infectious Disease, Cancer, Others), End-users (Hospi...
$ 3500
Quercetin Dihydrate Comprehensive Study by Application (Atherosclerosis, Chronic Infections, Cosmetics, Nutraceuticals, Allergy & Inflammation, Others), Form (Powder, Solution), Distribution Channel ...
$ 3450
Calcium Supplement for Pets Comprehensive Study by Type (Tablets, Gel Cap, Powder, Liquid), Application (Dogs, Cats, Others), Distribution Channel (Online, Offline) Players and Region - Global Market...
$ 3800
Enoxaparin Comprehensive Study by Application (Infectious Diseases, Gynecology, Cancer, Diabetes, Cardiology, Osteoporosis, Others), Age Group (Adults, Children (2 months to 18 yr), Infants (1 to 2 m...
$ 3450